Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System-Reference-Cited by-同舟云学术

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System

Published:2019-03-04 Issue:5 Volume:69 Page:2120-2135
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Goode Elizabeth C.¹²³⁴⁵^ORCID,Clark Allan B.⁴,Mells George F.²,Srivastava Brijesh²,Spiess Kelly²,Gelson William T.H.⁵,Trivedi Palak J.⁶⁷⁸,Lynch Kate D.⁹,Castren Edit¹,Vesterhus Mette N.¹⁰¹¹,Karlsen Tom H.¹⁰¹¹,Ji Sun‐Gou³^ORCID,Anderson Carl A.³,Thorburn Douglas¹²,Hudson Mark¹³,Heneghan Michael A.¹⁴,Aldersley Mark A.¹⁵,Bathgate Andrew¹⁶,Sandford Richard N.²,Alexander Graeme J.⁵¹²,Chapman Roger W.⁹,Walmsley Martine¹⁷,Hirschfield Gideon M.⁶⁷⁸¹⁸,Rushbrook Simon M.¹⁴,

Affiliation:

1. Norfolk and Norwich University Hospital Norwich United Kingdom

2. Academic Department of Medical Genetics Addenbrooke's Hospital, University of Cambridge Cambridge United Kingdom

3. Wellcome Trust Sanger Institute Hinxton, Cambridge United Kingdom

4. Norwich Medical School University of East Anglia Norwich United Kingdom

5. Cambridge Transplant Centre Addenbrooke's Hospital Cambridge United Kingdom

6. National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre Birmingham United Kingdom

7. Institute of Immunology & Immunotherapy University of Birmingham Birmingham United Kingdom

8. Centre for Rare Diseases, Institute of Translational Medicine University Hospitals Birmingham Birmingham United Kingdom

9. Translational Gastroenterology Unit John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford Oxford United Kingdom

10. Norwegian PSC Research Center, Department of Transplantation Medicine Oslo University Hospital Rikshospitalet Oslo Norway

11. Institute of Clinical Medicine, Faculty of Medicine University of Oslo Oslo Norway

12. Sheila Sherlock Liver Centre, Royal Free Hospital London United Kingdom

13. Liver Medicine and Transplantation Service Freeman Hospital Newcastle United Kingdom

14. Institute of Liver Studies Kings College Hospital London United Kingdom

15. Department of Hepatology Leeds Teaching Hospital Leeds United Kingdom

16. Scottish Liver Transplant Unit Royal Infirmary of Edinburgh Edinburgh United Kingdom

17. PSC Support Oxfordshire United Kingdom

18. Toronto Centre for Liver Disease University Health Network and University of Toronto Toronto Canada

Funder

PSC Partners Seeking a Cure

Addenbrooke's Charitable Trust, Cambridge University Hospitals

Isaac Newton Trust

Health Research

Department of Health, Australian Government

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30479

Reference33 articles.

1. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

2. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

3. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis

4. High lifetime risk of cancer in primary sclerosing cholangitis

5. Cancer surveillance in patients with primary sclerosing cholangitis

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis;Hepatology Communications;2024-01-29

2. Clinical factors associated with illness perception, worry and mental health in sclerosing cholangitis: A single centre prospective study;Clinics and Research in Hepatology and Gastroenterology;2024-01

3. Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis;JHEP Reports;2024-01

4. Prognostic models and autoimmune liver diseases;Best Practice & Research Clinical Gastroenterology;2023-12

5. Bile Acids in Autoimmune Liver Disease: Unveiling the Nexus of Inflammation, Inflammatory Cells, and Treatment Strategies;Cells;2023-11-29